Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin and Connective Tissue Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,107 result(s) found for: Skin and Connective Tissue Diseases. Displaying page 12 of 56.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2016-003952-63 Sponsor Protocol Number: LIQUENIA Start Date*: 2017-07-07
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: Pilot study of vulval lichen sclerosus treatment by adipose tissue associated with autologous platelet-rich plasma
    Medical condition: Vulval lichen sclerosus
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10047761 Vulval lichen sclerosus et atrophicus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005518-44 Sponsor Protocol Number: 15-01/GentaBet-C Start Date*: 2015-10-27
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Cream (Test) vs. Diprogenta(R) Cream (Reference) vs. Vehicle in patients with bacterial ...
    Medical condition: Bacterial infected eczemas
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10014199 Eczema infected PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005519-18 Sponsor Protocol Number: 15-02/GentaBet-S Start Date*: 2015-12-14
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Ointment (Test) vs. Diprogenta(R) Ointment (Reference) vs. Vehicle in patients with bact...
    Medical condition: Bacterial infected eczemas
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10014199 Eczema infected PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001297-63 Sponsor Protocol Number: MLORI201 Start Date*: 2023-04-13
    Sponsor Name:Melinta Therapeutics, LLC
    Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) RO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004500-30 Sponsor Protocol Number: ADSTEM001 Start Date*: 2015-02-13
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa
    Medical condition: Recessive dystrophic epidermolysis bullosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004955-35 Sponsor Protocol Number: 1883/12 Start Date*: 2013-07-29
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A single-center randomized double-blind placebo-controlled trial “Treatment of Systemic Sclerosis with Rituximab: evaluation of the effectiveness of B-cell depletion therapy”
    Medical condition: SYSTEMIC SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000391-15 Sponsor Protocol Number: AIFA-2016-02364869 Start Date*: 2018-06-05
    Sponsor Name:Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
    Full Title: Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis
    Medical condition: Myositis (dermatomyositis [DM] or polymyositis [PM])
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028653 Myositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004078-24 Sponsor Protocol Number: SARIPET_2019.099_version_1.1 Start Date*: 2020-05-07
    Sponsor Name:IDIVAL
    Full Title: Effect of Sarilumab on atherosclerotic disease measured by PET/CT (Positron Emission Tomography/Computed Tomography) in Rheumatoid Arthritis
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005215-41 Sponsor Protocol Number: 5.5 Start Date*: 2017-05-05
    Sponsor Name:Olli Leppänen
    Full Title: DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial comparing efficacy and ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10013872 Dupuytren's contracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004143-21 Sponsor Protocol Number: OA-orMSCp-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Bioinova, a.s.
    Full Title: Efficacy of autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. A randomized, controlled, open-label, multi-centre clinical trial.
    Medical condition: Knee Cartilage Defect
    Disease: Version SOC Term Classification Code Term Level
    27.0 10022117 - Injury, poisoning and procedural complications 10007710 Cartilage injury PT
    21.1 10022117 - Injury, poisoning and procedural complications 10007705 Cartilage damage LLT
    20.0 10042613 - Surgical and medical procedures 10057104 Cartilage repair LLT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10072638 Articular cartilage defect LLT
    20.0 10042613 - Surgical and medical procedures 10052913 Cartilage operation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002931-25 Sponsor Protocol Number: VP-VLY-686-2101 Start Date*: 2013-11-05
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT, ANTIPRURITIC STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN SUBJECTS WITH TREATMENT-RESISTANT PRURITUS ASSOCIATED WITH AT...
    Medical condition: Males or females with treatment resistant pruritus associated with atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002760-16 Sponsor Protocol Number: IB2015-04 Start Date*: 2015-10-19
    Sponsor Name:INSTITUT BERGONIE
    Full Title: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II stu...
    Medical condition: Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003688-39 Sponsor Protocol Number: CLS003-CO-PR-002 Start Date*: 2014-11-26
    Sponsor Name:Cutanea Life Sciences
    Full Title: A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in C...
    Medical condition: Patients with at least two warts who are otherwise healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10010115 Common warts LLT
    17.1 100000004864 10035158 Plantar warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005019-42 Sponsor Protocol Number: ET16-132 Start Date*: 2018-02-14
    Sponsor Name:Centre Léon Bérard
    Full Title: A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas pati...
    Medical condition: localised and operable soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000228-85 Sponsor Protocol Number: LP0084-1369 Start Date*: 2017-05-30
    Sponsor Name:LEO Pharma A/S
    Full Title: Incidence of squamous cell carcinoma and other skin neoplasia in subjects with actinic keratosis treated with ingenol disoxate gel 0.018% or 0.037%, or vehicle A phase 3 trial to compare the inc...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001974-32 Sponsor Protocol Number: CAIN457ADE04 Start Date*: 2015-04-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatme...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003501-25 Sponsor Protocol Number: ECM2013 Start Date*: 2014-02-20
    Sponsor Name:Mesoestetic Pharma group S.L.
    Full Title: Efficacy and safety of a 4% hydroquinone cream (Melanoderm 4%) for the treatment of melasma: a randomized controlled split-face study.
    Medical condition: Facial melasma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10027161 Melasma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000859-27 Sponsor Protocol Number: HS_Apremilast Start Date*: 2017-01-23
    Sponsor Name:Erasmus University Medical Center
    Full Title: Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study.
    Medical condition: Hidradenitis suppurativa, acne inversa, ectopic acne
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002959-42 Sponsor Protocol Number: 201712028 Start Date*: 2020-01-20
    Sponsor Name:Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche
    Full Title: Optimization of the use of anti-TNF antibodies in Verneuil's disease: Interest of a systematic initial prescription of methotrexate
    Medical condition: patient suffering from Verneuil's disease: Hurley II and III stages
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001048-70 Sponsor Protocol Number: CAIN457A2403 Start Date*: 2018-11-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A 16-week randomized, open-label, multicenter study to assess the superiority of secukinumab over guselkumab in the complete treatment of ustekinumab-resistant psoriatic plaques – ARROW
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:16:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA